RTP Mobile Logo

Interview with Daniel Pollyea, MD, MS


Track 1: Overview of acute myeloid leukemia (AML) in older patients
Track 2: Are older patients with AML receiving treatment?
Track 3: Case: An 83-year-old woman with AML receives azacitidine with venetoclax on a clinical trial
Track 4: Durable responses to venetoclax in combination with azacitidine or decitabine in elderly patients with AML
Track 5: Efficacy of venetoclax alone and in combination with hypomethylating agents (HMAs) for AML
Track 6: Management of treatment-associated tumor lysis syndrome (TLS)
Track 7: Biologic synergy of venetoclax and an HMA in AML
Track 8: Mechanism of action of venetoclax in AML
Track 9: Therapeutic targeting of AML stem cells
Track 10: Activity and tolerability of azacitidine/venetoclax in AML
Track 11: Quality of life with venetoclax
Track 12: Liposomal cytarabine/daunorubicin (CPX-351) for secondary AML
Track 13: Incidence of FLT3 mutations in AML; outcomes with approved and investigational FLT3 inhibitors
Track 14: Similarities and differences among midostaurin, quizartinib and gilteritinib
Track 15: Recently FDA-approved IDH1/2 inhibitors enasidenib and ivosidenib for patients with AML
Track 16: Recognition and management of differentiation syndromes in patients with AML treated with IDH or FLT3 inhibitors
Track 17: Clinical experience with enasidenib in patients with AML and IDH2 mutations
Track 18: Case: A 48-year-old man with relapsed/refractory AML and an IDH1 mutation receives ivosidenib
Track 19: Case: A 28-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL) receives the bispecific T-cell engaging antibody blinatumomab
Track 20: Challenges in using pediatric-inspired induction chemotherapy for adults with high-risk Philadelphia chromosome-negative ALL
Track 21: Mechanism of action and side effects of blinatumomab
Track 22: Current role of chimeric antigen receptor (CAR) T-cell therapy in ALL
Track 23: Case: A 38-year-old woman with acute promyelocytic leukemia receives all-trans retinoic acid and arsenic trioxide

Interview with Jorge E Cortes, MD

Track 1: Potential undertreatment of AML in elderly patients
Track 2: Safety and preliminary efficacy of venetoclax in combination with an HMA for elderly patients with previously untreated AML
Track 3: Management of venetoclax-associated TLS and myelosuppression
Track 4: Use of venetoclax/decitabine as salvage therapy for younger patients with relapsed/refractory AML
Track 5: Case: A 68-year-old man with a history of previously treated Hodgkin lymphoma presents with secondary AML and an IDH1 mutation
Track 6: Activity and tolerability of liposomal cytarabine/daunorubicin in patients with secondary AML
Track 7: Case: A 47-year-old man with relapsed/refractory AML and an IDH2 mutation receives enasidenib on a clinical trial
Track 8: Incidence of IDH1/2 mutations in AML; integration of enasidenib and ivosidenib into clinical practice
Track 9: Case: A 65-year-old man with previously untreated AML and a FLT3-ITD mutation experiences a complete remission with midostaurin and chemotherapy
Track 10: Similarities and differences among approved and investigational FLT3 inhibitors
Track 11: Activity and tolerability of FLT3 inhibitors alone or in combination with HMAs
Track 12: Choosing between gilteritinib and quizartinib
Track 13: Voluntary market withdrawal of the antibody-drug conjugate gemtuzumab ozogamicin and recent FDA reapproval for AML
Track 14: Clinical use of gemtuzumab for patients with low- to intermediate-risk AML and no adverse cytogenetics
Track 15: Activity and unique side-effect profile of the investigational hedgehog inhibitor glasdegib in AML
Track 16: Treatment selection for younger and older patients with ALL
Track 17: Activity and side effects of asparaginase preparations for ALL
Track 18: Responses and tolerability with the antibody-drug conjugate inotuzumab ozogamicin in patients with ALL
Track 19: FDA-approved indications for blinatumomab in ALL and management of immune-related side effects
Track 20: Effectiveness of CAR T-cell therapies for ALL
Daniel Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
Jorge E Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Chief, CML and AML Sections
Deputy Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Neil Love, MD
Research To Practice
Miami, Florida